Akoya Biosciences Inc

NASDAQ AKYA

Download Data

Akoya Biosciences Inc Days Payable Outstanding (DPO) 2 year CAGR for the quarter ending March 31, 2024: -20.24%

Akoya Biosciences Inc Days Payable Outstanding (DPO) 2 year CAGR is -20.24% for the quarter ending March 31, 2024, a -145.14% change year over year. The days payables outstanding ratio measures the average number of days it takes for a company to pay its suppliers. It is calculated by dividing accounts payable by the cost of revenue and then multiplying by 365. This ratio indicates the average payment period for suppliers and reflects the efficiency of managing trade payables. A longer period suggests extended payment terms and potential working capital advantages. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Akoya Biosciences Inc Days Payable Outstanding (DPO) for the quarter ending March 31, 2023 was 920.13, a 48.78% change year over year.
  • Akoya Biosciences Inc Days Payable Outstanding (DPO) for the quarter ending March 31, 2022 was 618.43, a 41.01% change year over year.
  • Akoya Biosciences Inc Days Payable Outstanding (DPO) for the quarter ending March 31, 2021 was 438.58.
NASDAQ: AKYA

Akoya Biosciences Inc

CEO Mr. Brian McKelligon
IPO Date April 16, 2021
Location United States
Headquarters 100 Campus Drive, Marlborough, MA, United States, 01752
Employees 330
Sector Healthcare
Industry Medical instruments & supplies
Description

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Similar companies

ANGO

AngioDynamics Inc

NA

NA

PDEX

Pro-Dex Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email